Observations placeholder
Rosiglitazone
Identifier
005507
Type of Spiritual Experience
Background
A description of the experience
Rosiglitazone is marketed as the stand-alone drug Avandia and in combination with metformin as Avandamet or with glimepiride as Avandaryl . It is a Thiazolidinediones.
At one time it was a very high selling drug. Annual sales peaked at approximately $2.5bn in 2006, but declined after reports of adverse effects. In Europe, the European Medicines Agency (EMA) recommended in September 2010 that the drug be suspended from the European market. The FDA concluded that although the use of rosiglitazone for the treatment of type 2 diabetes was associated with a greater risk of myocardial ischemic events (including heart attacks) than a placebo, rosiglitazone was no different to metformin, or the sulfonylureas in the risk of heart attack – they all shared the risk.
All TZDs are contraindicated in patients with NYHA Class III and IV heart failure.
On Jan, 30, 2017 4,542 people reported to have side effects when taking Rosiglitazone. Among them, 4 people (0.09%) have Hallucination
On Mar, 31, 2015: 3,946 people reported to have side effects when taking Rosiglitazone. Among them, 710 people (17.99%) have Death.
Time on Rosiglitazone when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 0.00% | 10.87% | 4.35% | 18.48% | 44.57% | 21.74% | 0.00% |
Gender of people who have Death when taking Rosiglitazone :
| Female | Male | |
| Death | 38.68% | 61.32% |
Age of people who have Death when taking Rosiglitazone :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 0.00% | 6.59% | 12.64% | 15.38% | 65.38% |
On Mar, 31, 2015: 2,496 people reported to have side effects when taking Rosiglitazone maleate. Among them, 572 people (22.92%) have Death.
Time on Rosiglitazone maleate when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 0.00% | 11.59% | 4.35% | 18.84% | 40.58% | 24.64% | 0.00% |
Gender of people who have Death when taking Rosiglitazone maleate :
| Female | Male | |
| Death | 40.29% | 59.71% |
Age of people who have Death when taking Rosiglitazone maleate :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 0.00% | 4.41% | 11.76% | 13.24% | 70.59% |